Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 762

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 762
---
, and should be applied prospectively. The Company is currently evaluating the impact of the update on the Company’s consolidated financial statements and related disclosures. F-14

Except as disclosed elsewhere, there have been no new, or existing, recently issued accounting pronouncements that are of significance, or potential significance, that impact the Company’s consolidated financial statements. 3. Clinical trial deposit In October 2020, the Company announced that it had entered into a final agreement with a contract research organization (“CRO”) for the management of the Company’s registrational study of VAL-083for glioblastoma. Under the agreement, the Company supplied the drug for the study and the CRO managed all operational aspects of the study including site activation and patient enrollment. The Company was required to make certain payments under the agreement related to patient enrollment milestones. For the year ended June 30, 2024, the Company has recognized an expense of $ 563(2023 - $ 5,065), respectively, for this study in relation to clinical site initiation and patient enrollment. On October 31, 2023, the Company announced that preliminary topline results from this registrational study for VAL-083did not perform better than the current standards of care in glioblastoma. As a result, the Company announced that it has terminated the development of VAL-083.In the year ended June 30, 2024, the remaining deposit of $ 1,075was offset against amounts owing to the CRO and the agreement with the CRO was terminated with an additional final cost of $ 1,000, which was paid in the year ended June 30, 2024. In the year ended June 30, 2024, the Company recorded $ 205as a deposit with a CRO for the management of the Company’s 15-patientstudy of REM-001for cutaneous metastatic breast cancer (“CMBC”). 4. Clinical trials grant Effective July 1, 2023, the Company was awarded a $ 2,000Small Business Innovation Research grant from the National Institutes of Health (“NIH”) to support the clinical development of REM-001for the treatment of cutaneous metastatic breast cancer. The grant will be received in twotranches: approximately $ 1,250for the period July 1, 2023, to June 30, 2024, and approximately $ 750for the period July 1, 2024, to June 30, 202